Background: The bypassing agent factor VII (FVIIa) is a first-line therapy for the treatment of acute bleeding episodes in patients with haemophilia and high-titre inhibitors. FVIIa is a highly post-translationally modified protein that requires eukaryotic expression systems to produce a fully active molecule. A recombinant FVIIa was produced in the milk of transgenic rabbits to increase expression and provide an efficient, safe and affordable product after purification to homogeneity (LR769). Aim: To present the biochemical and functional in vitro characteristics of LR769. Results: Mass spectrometric analyses of the intact protein and of heavy and light chains revealed a fully activated, mature and properly post-translationally modified protein notably regarding N/Oglycosylations and c-carboxylation. Primary structure analysis, performed by peptide mapping, confirmed 100% of the sequence and the low level or absence of product-derived impurities such as oxidized, deamidated and glycated forms. Low levels of aggregates and fragments were observed by different chromatographic methods. Higher order structure investigated by circular dichroism showed appropriate secondary/tertiary structures and conformational change in the presence of Ca 2+ ions. Finally, activated partial thromboplastin time and thrombin generation assays showed the ability of LR769 to decrease coagulation time and to generate thrombin in haemophiliac-A-plasmas, even in the presence of inhibitors. Conclusion: The innovative expression system used to produce LR769 yields a new safe and effective rhFVIIa for the treatment of haemophilia A or B patients with inhibitors.
Introduction
Factor VII (FVII) or proconvertin is a vitamin K-dependant plasma glycoprotein involved in the coagulation cascade. The active protein (FVIIa) is composed of a 20-kDa 152-residue light chain and a 30-kDa 254-residue heavy chain which contains the catalytic domain; the two chains are held together by a disulphide bond [1] . The protein is highly homologous to other vitamin K-dependent proteins and contains a number of post-translational modifications (PTMs) that is 10 gamma-carboxyglutamic acid residues (GLA), two O-glycosylations at Ser 52 and Ser 60 , one b-hydroxylation at Asp 63 [2] and two N-glycosylation at Asn 145 and Asn 322 positions. FVII circulates as a single-chain zymogen form that is converted by different proteases into an active enzyme (FVIIa) once bound to tissue factor (TF) following vessel injury [3] . FVIIa is able to bypass the factor VIII/IX-dependent step in the coagulation cascade to promote haemostasis and is in this way used to control bleeding episodes and in prevention of bleeding during surgical interventions or invasive procedures. Two non-exclusive mechanisms of action of FVIIa as a bypassing agent (BPA) are actually proposed, one involving the binding of FVIIa to activated platelets and the second one based on the competition with FVII zymogen for the available TF [4, 5] . To date, NOVOSEVEN (Novo Nordisk A/S, Novo All e, Bagsvaerd Denmark) is the principal recombinant FVIIa indicated for the treatment of patients with congenital or acquired haemophilia with inhibitors to FVIII or FIX and patients with congenital FVII deficiency [6] . It is expressed in baby hamster kidney cells and secreted into the culture media containing foetal bovine serum used as serum supplement for the in vitro cell culture of eukaryotic cells. The choice of eukaryotic cells is driven by the fact that FVIIa is a highly post-translationally modified protein with PTMs required for its full bioactivity.
Production of recombinant proteins in the milk of transgenic farm animals (lactorecombinant) is an emerging new technology. Animals are used as bioreactors to produce large and complex proteins which bring several advantages over conventional cell culture systems: the protein can be recovered easily by milking animals, secretion of proteins by the mammary glands is usually very high and upstream scale-up is very consistent and amenable because it is only achieved by increasing the number of lactating animals. As a consequence, biopharmaceutical production from the milk of transgenic animals could overcome problems of low yields and production scale-up issues associated with current mammalian cell cultures [7] [8] [9] . In the present report, we investigated the structure and function of a new recombinant human FVIIa (rhFVIIa, LR769) produced in the milk of transgenic rabbits [7] . A wide range of analytical approaches were used to characterize this product; LR769 primary structure, PTMs, purity and integrity were assessed by chromatography and mass spectrometry, circular dichroism (CD) was used for higher order structure testing and activity was investigated by both thrombin generation (TG) and activated partial thromboplastin time (aPTT).
Materials and methods

Materials
LR769 (rhFVIIa, SEVENFACT, LFB BIOTECHNOL-OGIES, Les Ulis, FRANCE) was derived from a representative reference batch available at LFB Biotechnologies. It is produced in a line of specific pathogen-free rabbits which have a recombinant DNA transgene stably integrated into their genome. The transgene used in generation of the transgenic rabbits contains a synthetic gene coding for hFVII together with a mammary gland promoter which results in sitedirected expression of rhFVII in the mammary gland (rPRO technology, rEVO Biologics, Framingham, MA, USA [10] ). Milk was collected, pooled, clarified and the protein is purified, activated on an anion exchange resin in the presence of Ca 2+ as described by Tomokiyo et al. [11] and stabilized to yield a stable biologically active rhFVIIa molecule of suitable identity, quality, purity and potency. One source of recombinant FVIIa was used as comparator for this study (batch CS6G541; NOVOSEVEN). NOVOSE-VEN was reconstituted according to manufacturers' recommendations (Novo Nordisk A/S).
Frozen individual platelet-poor plasma issued from patients with severe haemophilia A were from Cryopep (Montpellier, France). Plasmas without inhibitors (7-0800, batch 899-3286) and with inhibitors (7-1800, batch 1838-3068, 176 BUÁmL À1 ) were used for aPTT and thrombin generation assays (TGAs).
Pathromtin SL and 0.025 M CaCl 2 reagents were from Siemens Healthcare (Marburg, Germany). Tissue factor, thrombin calibrator solution, Fluo-buffer and Fluo-substrate were from Diagnostica Stago (Asni eres sur Seine, France). Dithiothreitol (DTT), iodoacetamide (IAM), urea, ammonium acetate, ethylenediaminetetraacetic acid (EDTA), phosphate buffered saline (PBS), calcium chloride (CaCl 2 ), acetic acid (CH 3 COOH), formic acid (FA), sodium acetate (CH 3 COONa), Guanidine hydrochloride (GuHCl) and Orbitrap calibration kit were purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA). Trypsin was purchased from Roche (Mannheim, Germany). Acetonitrile (MeCN) was HPLC reagent grade and purchased from JT Baker (Philipsburg, NJ, USA). Methanol (MeOH) was HPLC reagent grade and purchased from Biosolve (Leenderweg, the Netherlands). Trifluoroacetic acid (TFA) was from Merck Biosciences (Darmstadt, Germany). All the aqueous solutions were prepared using ultra-pure water (18.2 MΩ-cm resistivity, at 25°C, total organic carbon (TOC) <5 ppb).
Size exclusion chromatography (SEC)
rhFVIIa (50 lg) was injected onto an UPLC BEH125 SEC column (300 9 4.6 mm, 1.7 lm) equilibrated at 30°C using an ACQUITY UPLC H-class bio system (Waters, Milford, MA, USA). The following mobiles phases were used: A NaH 2 PO 4 100 mM, B Na 2 HPO 4 125 mM, C NaCl 1 M and D H 2 O. The flow rate was set at 0.3 mLÁmin
À1
, and the Auto Blend Plus function was used to mix the mobiles phases in order to reach a final mobile phase at pH 7.0 and 250 mM NaCl to separate species based on size. After separation, relative amounts of rhFVIIa multimers, monomer and fragments were quantified using peak absorbance at 280 nm.
Reverse-phase chromatography (RP-HPLC) in non-reducing conditions Separation was carried out on an Acquity system (Waters) coupled to an UV detector. rhFVIIa (7 lg) was injected on a Pursuit diphenyl column (150 9 2.0 mm, 3 lm) equilibrated at 40°C (Agilent, Santa Clara, CA, USA) and operated at a flow rate of 250 lLÁmin
. An aqueous solution containing 0.1% TFA and MeCN containing 0.1% TFA were, respectively, used as buffer A and buffer B; sample was eluted using an increasing gradient of buffer B. After separation, oxidized forms of hFVIIa were quantified using peak absorbance at 214 nm. MS analysis of the intact protein was achieved by interfacing the UV detector output to a SYNAPT G2-S HDMS mass spectrometer (Waters) scanning from m/ z 500 to 2000.
Reverse-phase chromatography (RP-HPLC) in reducing conditions rhFVIIa (100 lg) was vacuum-dried and dissolved in 50 lL of a 8 M urea and 0.4 mM ammonium carbonate solution pH 8.0. Reduction was performed by adding 10 lL of a 100 mM DTT solution in water and incubating the resulting mixture for 15 min at 55°C. After cooling at room temperature, 10 lL of a 200 mM IAM solution in water was added and the solution was incubated at room temperature for 15 min in the dark. The solution is next diluted to 200 lL QSP with a 10 mM EDTA solution. Reverse-phase (RP)-HPLC was performed using an ACQUITY UPLC system (Waters). An amount of 25 lg of sample was injected on a Vydac reverse-phase C4 column (150 9 2.1 mm, 5 lm) equilibrated at 40°C and operated at a flow rate of 350 lLÁmin À1 (Grace, Albany, NY, USA). Proteins were eluted using an increasing gradient of buffer B (as described previously). After separation, cleaved product impurities were quantified using their peak absorbance at 214 nm. MS analysis of light and heavy chains was achieved by interfacing the UV detector output to a SYNAPT G2-S HDMS mass spectrometer (Waters) scanning from m/z 500 to 2000.
Peptide mapping (LC-MS/MS)
rhFVIIa (200 lg) was vacuum-dried and dissolved in 25 lL of 8 M urea, 0.2 M ammonium acetate solution pH 7.2. Reduction was accomplished by adding 10 lL of a 200 mM DTT solution in water and incubating the resulting mixture for 15 min at 55°C. After cooling at room temperature, 10 lL of a 400 mM IAM solution in water was added and the solution was incubated at RT for 15 min in the dark. After an eightfold dilution with water, digestion with trypsin (1:10, w/w) was performed overnight at 37°C. Peptides obtained after digestion (40 lg) were injected on a CSH C18 column (2.1 9 150 mm, 1.7 lm) using an ACQUITY UPLC system interfaced with a SYNAPT G2-S HDMS mass spectrometer (Waters). The column was equilibrated at 60°C and operated at a flow rate of 300 lLÁmin
À1
. An aqueous solution containing 0.1% FA and MeCN containing 0.1% FA were, respectively, used as buffer A and buffer B; proteins were eluted using an increasing gradient of buffer B. Peptides were also analysed on a nano-LC system (U3000) interfaced with a highresolution LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using an Acclaim PepMap100 C18 column (0.075 9 150 mm, 3 lm) as previously described [12] .
Circular dichroism experiments
Far-UV (ultraviolet, 185-260 nm) CD spectrum is used to reveal important characteristics of proteins secondary structure and folding. CD spectra were recorded on a J-810 spectropolarimeter (Jasco, Cremella, Italy). The instrument was calibrated using 10-camphorsulfonic acid [13] . All experiments were performed in 10 mM Borate (pH 6.0) with 0 or 5 mM Ca 2+ . The protein concentration was 0.1 gÁL
À1
, and the sample was placed in a cuvette with a 1-mm path length at room temperature. For thermal perturbation experiments, the temperature of the chamber was raised from 35 to 70°C using a heating rate of 1°CÁmin
. Each spectrum was the result of three scans obtained by collecting data at 0.2-nm intervals from 185 to 260 nm. At high temperatures and absence of Ca 2+ ions, secondary structures are partially modified leading to shifts of positive and negative bands. For this reason, a thermal denaturation curve in the absence of Ca 2+ ions was not obtained by plotting the variation of ellipticity at a fixed wavelength (poor observable transition) but instead by plotting the relative zero-signal wavelength variation in function of the temperature to observe a denaturing transition. In the presence of Ca 2+ ions, a transition after thermal denaturation was clearly observed by plotting variation of ellipticity at 210 nm as a function of temperature. Chemical perturbation of the secondary structure of rhFVIIa was measured by monitoring signal at 222 nm as a function of GuHCl concentration. The recorded spectra were obtained at 20°C using a cuvette with a 1-mm path length. The protein concentration was 0.1 gÁL À1 , and the solution was allowed to equilibrate overnight at room temperature for each GuHCl concentration before CD acquisition [14] . Each spectrum was the result of three scans obtained by collecting data at 0.2-nm intervals from 200 to 260 nm. The denaturation curves were fitted against a 'sigmoidal dose-response' model with a variable slope using the GRAPHPAD Prism software and a top value constrained to 100% (GRAPHPAD Software, La Jolla, CA, USA).
Activated partial thromboplastin time (aPTT)
Fifty microlitres of rhFVIIa-spiked plasmas (0-1 lgÁmL À1 rhFVIIa range) from haemophiliac with or without inhibitors and 50 lL of Pathromtin SL were mixed. Tubes were incubated at 37°C during 120 s. Then, the coagulation was started with 50 lL of 0.025 M CaCl 2 and the signal was measured during 160 s at 405 nm on a BCS-XP system from Siemens Healthcare (Marburg, Germany). In our laboratory, normal plasma gives an aPTT comprised between 30 and 40 s (data not shown).
Thrombin generation assay (TGA)
Generation of thrombin (TG) was measured in highbinding 96-well Immulon 2 HB microplates from Thermo Scientific (Waltham, MA, USA) by comparing fluorescence generated in the sample after clotting activation with TF (in TG wells) to the fluorescence of a calibrated thrombin solution (in Cal wells) using a Fluoroskan Ascent from Thermo Scientific (Waltham, MA, USA). In each well, 80 lL of plasma samples spiked or not with rhFVIIa was added to 20 lL of a buffer solution containing the trigger substrate (TF at 1 pM) in TG wells, or 20 lL of thrombin calibrator solution in Cal wells. Then, 20 lL of the HEPESCaCl 2 solution Fluo-buffer was added in the TG and Cal wells, respectively, to initiate TG. The final mixture contained 1 pM of TF and 4 lM of phospholipids. Fluorescence was measured in each well of the microplate, and the software converted the signal to calculated molar concentrations of thrombin during the time of the experiment. All analyses were performed in quadruplicate and rhFVIIa was spiked at four tested doses (0.25, 0.5, 0.75 and 1 lgÁmL À1 ). All the curve parameters were recorded but only the area under the curve or endogenous thrombin potential (ETP) and the velocity (slope between the end of lag time and peak thrombin) were discussed in this study as other parameters were not more relevant.
Results
Structural characterization
The primary sequence of LR769 was thoroughly investigated. Figure 1 shows the ESI mass spectrum of the intact molecule as well as its SDS-PAGE pattern provided in insert in both Coomassie Blue and Silver staining. Mass spectrometry gives a major experimental mass of 49 608 Da, consistent with the mass of the sequence [Ala 1 -Pro 406 ] modified by nine c-carboxylations, one fucose and one glucose at Ser 52 and Ser 60 , respectively, two biantennary monosialylated N-glycans (A 2 G 2 S 1 ) corresponding to N-glycosylations at Asn 145 and Asn 322 and addition of one molecule of water related to the activation of LR769 (Theoretical mass of 49 607 Da). LR769 gives a major homogeneous band at an apparent molecular weight (MW) of 47 kDa by SDS-PAGE slightly below its expected one in accordance with the more compact structure of proteins in non-reducing conditions that migrates at lower MW. Minor bands were also observed in Silver staining, corresponding to cleaved forms of rhFVIIa (43, 37 and 14 kDa) and to the heavy chain (28 kDa).
After reduction, the molecule separates into two polypeptide chains confirming that LR769 is fully activated. Figure 2 shows the ESI mass spectra of the reduced and alkylated heavy and light chains. For the light chain (see Fig. 2a ), the detected masses were consistent with the presence of two O-glycosylated structures (Glc and Fuc), nine c-carboxylations and one N-glycosylation. Several N-glycan structures of the high-mannose, hybrid and complex type were detected. The experimental mass of 20 501 Da, observed for the major form, is consistent with the Nglycosylation of the rhFVIIa light chain by A 2 G 2 S 1 (theoretical mass of 20 501 Da). Same types of N-glycan structures were detected on the heavy chain (see Fig. 2b ) with a major experimental mass of 30 499 Da consistent with an A 2 G 2 S 1 glycosylated form (theoretical mass of 30 500 Da). A previous LR769 glycosylation analysis [7] showed the absence of immunogenic a-1,3-Gal and N-glycolyl-neuraminic acid epitopes. ESI mass spectra of NOVOSEVEN heavy and light chains were provided in Figure S1 , showing masses consistent with similar sequence and PTMs except for N-glycosylation composed exclusively of sialylated complex structures with some of them carrying a terminal N-acetylgalactosamine expected to be cleared rapidly by the asialoglycoprotein receptor [15] .
The sequence coverage of LR769 was investigated by peptide mapping with both trypsin and AspN enzymes. The theoretical sequence was fully covered and consistent with experimental MS and MS/MS of the peptides.
Post-translational modifications were also investigated at the peptide level. The N-terminal peptide [Ala 1 -Arg 36 ] was identified (see Fig. 3a ) with an accurate monoisotopic mass of 4768.0 Da (see the 4+ charge state in insert) in accordance with the addition of nine GLA residues (theoretical mass of 4768.0 Da). The MS/MS mass spectrum of this peptide confirms the sequential loss of nine carboxylic acids (see Fig. 3b ) in the gas phase of the mass spectrometer as c-carboxylation is known to be a labile modification [16] . Interestingly, MS and MS/MS data of peptide [Ala 1 -Lys 32 ] are also in agreement with a content of nine GLA residues which indicates that Glu 35 is not c-carboxylated. Hence, LR769 possesses nine c-carboxylated Glu residues of the 10 potential sites, Glu 35 being not c-carboxylated as already reported for another rhFVIIa molecule [17] . The propeptide was not detected either at the peptide or protein level indicating the full maturation of LR769. Asp 63 was found partially b-hydroxylated at about 4% according to peak-to-peak relative intensities of m/z 701.99 and 707.32 corresponding, respectively, to the non-modified and b-hydroxylated triply charged peptide [Asp 63 -Arg 79 ] (see Figure S2 ). Met 298 and Met 306 of the heavy chain were weakly oxidized at <1% for each of them based on peak-to-peak relative intensities of non-oxidized vs. Figures S3 and S4 ). Other potential forms of protein degradation such as deamidation, aspartic acid isomerization or glycation were not detected suggesting that upstream and downstream processes are suitable to the production and purification of a homogeneous mature FVIIa molecule.
Product-related impurity determination
Product-related impurities were investigated by several chromatographic methods. Size exclusion chromatography (SEC) was used firstly to assess the level of aggregates and fragments (see Fig. 4a ). Purity of the monomer was estimated at 95.7%. Aggregates were quantified at 1.6% and were mostly constituted of rhFVIIa dimers. Cleaved forms eluting after the main peak were detected at 2.7%. RP-HPLC in nonreducing conditions (see Fig. 4b ) was used to assess oxidized forms of rhFVIIa that elute faster than the native product due to their higher polarity [18] . LR769 displays a RP-chromatographic pattern with a main peak corresponding to the native intact product, estimated at 95% of the total UV signal. A series of minor peaks eluting in front of the main peak were identified by MS as oxidized forms at Met 298 and Met 306 and estimated at a cumulated level of 2.3%. Finally, the first eluting peak was identified as cleaved forms of rhFVIIa at Arg 290 leading to the loss of a 15-kDa C-terminal heavy chain fragment (FVIIa-c form). This minor cleavage represented 2.7% of the total signal. Reverse-phase-HPLC in reducing conditions (see Fig. 4c ) was used to assess all the cleaved forms of rhFVIIa [19] while the previous analyses detected only the FVIIa-c form. These cleaved forms correspond to 'trypsin-like' cleavages of the light chain at Lys 32 and Lys 38 sites (DESGLA) and of the heavy chain at Arg 290 (FVIIac form) and Arg 315 (FVIIab form) sites, as previously described [20] . Integration of peaks related to these four cleavage sites estimated a total content of cleaved forms of 11%.
Higher order structure
Secondary structures were investigated by CD in the far-UV range. In the absence of Ca 2+ ions, the obtained CD spectrum was characterized by a positive band at 187 nm and a negative band at 212 nm (see Fig. 5 ). The overall spectrum profile suggests a relatively high content of bstructures, as expected. In the presence of 5 mM Ca 2+ , a redshift was observed with an increase in intensity of the maximum at 191 nm and the negative band slightly blueshifted at 210 nm with an increase of signal amplitude. This CD signal variation is indicative of a structural change that argues indirectly for the binding of Ca 2+ ions to the protein. Changes in secondary structures upon thermal denaturation were monitored by CD in the far-UV region. Figure 6a shows the thermal denaturation curves obtained in the absence and presence of Ca 2+ ions. In our experimental conditions, the estimated T m values were of 51 and 58°C, respectively. The HillSlope parameter deduced from the fit was three times higher in Ca 2+ condition (0.14 vs. 0.42), reflecting a steeper slope as the result of a qualitative higher Van't Hoff enthalpy of unfolding (not determined). Figure 6b shows the chemical denaturation curves obtained in Ca 2+ -free and Ca 2+ conditions. The two denaturation curves were fairly similar and displayed a sigmoidal shape. In Ca 2+ condition, a rapid but moderate change of ellipticity was observed at the first point of GuHCl concentration (0.5 M) relatively to the initial state but not in the absence of Ca
2+
. This difference explains the slight shift observed between the two curves as relative ellipticity change was plotted in both conditions. In our experiments, the major transition attributed to the protein unfolding was found between 2.7 and 2.9 M GuHCl.
Functional assays
Activated partial thromboplastin time is a performance indicator of the efficacy of both the contact activation and the common coagulation pathways. The two haemophiliac-A-plasmas (with or without inhibitors) showed prolonged aPTT compared to normal value indicating the low concentration of FVIII in these plasmas. Addition of rhFVIIa (either LR769 or NOVOSEVEN) in the reaction mixture shortened the aPTT with a dose-effect response both in haemophiliac-A-plasmas without inhibitors and with a high titre (176 BUÁmL
À1
) of inhibitors (see Fig. 7a,b) . The normal aPTT range was nevertheless not completely reached in vitro even at the highest dose of 1 lgÁmL À1 rhFVIIa. Finally, the two tested rhFVIIa lead to identical results at all tested doses and types of plasma. Figure 8a ,b, respectively, show TG curves and velocity parameters determined in haemophiliac-Aplasmas without and with inhibitors after spiking of LR769 and NOVOSEVEN. When rhFVIIa was added at the lowest tested concentration (0.25 lgÁmL
), an important increase of velocity was observed in all tested plasmas. Then, a slight dose-dependant increase was observed indicating the presence of an activity plateau. At the different tested concentrations from 0.25 to 1 lgÁmL
, the two rhFVIIa-tested products lead to perfectly stackable curves showing the same efficiency to generate thrombin in the presence of phospholipids and TF (i.e. similar ETP and velocity).
Discussion
Production of recombinant medicines using cell-based expression systems is a time-consuming process, requiring expensive and complex bioreactor equipment and facilities. The use of animals as bioreactors provides an innovative approach to produce complex proteins with high expression levels and scalability. Today, two therapeutic proteins isolated from the milk of transgenic animals, C1 inhibitor (Ruconest â , PHARMING, Leiden, THE NETHERLANDS) and antithrombin (ATryn â , rEVO Biologics, Framingham, MA, USA), obtained their marketing authorization both in USA and Europa [21] . The production of FVIIa using this new technology should improve the availability of this therapeutic protein. This report provides the first detailed structural and functional analysis of LR769, a novel rhFVIIa, currently evaluated in a multinational Phase 3 clinical trial designed to test its ability to treat or prevent bleeding episodes for surgeries and procedures in adolescent and adult congenital haemophilia A or B patients with inhibitors. MS analysis of the intact molecule and of reduced heavy and light chains provides valuable information regarding the overall structure of the molecule. Observed masses are consistent with a fully activated, mature and post-translationally modified human FVII sequence. Orthogonal peptide mapping experiments confirm also that the molecule releases, after specific digestion, the expected peptides deduced from the DNA coding sequence. Appropriate c-carboxylation is demonstrated with the N-terminus of the protein detected with nine GLA residues described as adequate for proper Ca 2+ binding and full activity of the protein, the last Glu 35 residue being not required [22] . The major observed N-glycan structure is of the complex monosialylated biantennary type, and the distribution of the N-glycan structures appears quite homogeneous between the two sites. More generally, the detected glycans are highly similar to those described for the C1 inhibitor produced in the same expression system and highly reproducible either from batch to batch or after scale-up [7] . Noticeably, recombinant proteins expressed so far in the mammary glands of rabbits do not contain any Galili or Hanganudtziu Deicher immunogenic epitopes [7, 23, 24] . Rabbit milk contains a significant amount of reducing lactose 1.7 g/100 g dry matter [25] , but glycated rhFVIIa peptides resulting from putative Maillard reactions [26] were not observed. This result indicates an appropriate control from the raw material collection up to the drug product manufacturing.
Pedersen et al. [27] described that FVII is capable of autoactivation, the activated molecule being then able to cleave itself into undesirable fragments of reduced activity [28] . RP-HPLC analysis in reducing conditions shows that the manufacturing process of LR769 delivers an activated molecule with reasonably low product-derived cleaved impurities. Similarly, oxidized and aggregated impurities were shown to be appropriately managed and minimized by the purification process and both Met 298 and Met 306 were identified as the most sensitive to oxidation as already described [18] . Altogether, all these product-derived impurities were also found to be of the same order of magnitude as those published for NOVOSEVEN [29] . It should also be outlined that because of the final high purity of LR769, traces of milk proteins at low ppm were not detected by these methods.
CD spectra indicated a high prevalence of b-structures. This result is in close accordance with data reported by Beals et al. [30] on vitamin K-dependent blood coagulation proteins showing that bovine factor IX, X and prothrombin were similar in their ordered secondary structures, with a large prevalence of b-sheet and b-turn structures. In an interesting study involving far-UV CD spectroscopy, Freskgard et al. [31] observed a redshift of about 2 nm of the positive band around 188 nm and an increase in a-helical structures upon Ca 2+ binding to FVII. Using GLA-domain-less and GLA-domain-only constructs, they demonstrated that the GLA domain is responsible for these structural changes. A similar change of the CD profile after Ca 2+ adding was obtained with the LR769 molecule, demonstrating its ability to bind Ca 2+ ions through its N-terminal GLA domain. Thermic denaturation curves show that the unfolding transition is dependant of Ca 2+ ions as well with a T m shift from 51 to 58°C. This clear increase of T m observed in Ca 2+ conditions has been described previously for FIX [32] , PC [33] and FVIIa [14] using differential scanning calorimetry. In the presence of Ca 2+ ions, the unfolding transition has been described as the cooperative unfolding of the serine protease domain and the interacting Ca 2+ -loaded GLA domain [33] . Chemical denaturation using increasing concentration of a chaotropic buffer (GuHCl) gave an unfolding transition at about 2.7-2.9 M. Differences observed between Ca 2+ and Ca 2+ -free conditions were not significant excepted for the slight variation of ellipticity at low GuHCl concentration in Ca 2+ conditions. These results are also in close accordance with those reported previously for a recombinant FVIIa by intrinsic fluorescence, dansyl fluorescence and circular dichro€ ısm [14] . In their study, the authors observed, in the presence of Ca 2+ ions, a first denaturation transition at about 0.3 M GuHCl attributed to the unfolding of the Ca 2+ -structured GLA domain and a second transition at about 3 M GuHCl reflecting the unfolding of the SP domain.
Finally, two functional assays were performed to demonstrate similar in vitro activity of LR769 vs. NOVOSEVEN. Conventional assays like aPTT are useful to monitor coagulation defects in both extrinsic and intrinsic pathways but cannot be used to predict the clinical effect of BPA because the monitoring of fibrin formation as endpoint of coagulation catch only the generation of thrombin at the end of the initiation phase and not the 95% of thrombin generated after clot formation during the propagation phase [34, 35] . In our aPTT experiment, the clotting time was nevertheless reduced with increasing dose of rhFVIIa in haemophiliac-A-plasmas, even in the presence of inhibitors. The response of the two tested recombinant products was perfectly similar for same doses which suggested an overall functional equivalence at least considering their ability to initiate coagulation through TF and phospholipids binding. This result is also consistent with the fact that the two recombinant products display similar binding to TF when tested by surface plasmon resonance (data not shown). The TGA is more global and measures the overall tendency of a plasma sample to form thrombin after initiation of coagulation. The TG curve, which is characterized by a lag phase followed by the formation and subsequent inhibition of thrombin, reflects all three phases of coagulation (initiation, propagation and termination). LR769 and NOVOSEVEN both increase TG in haemophiliac-A-plasmas with and without inhibitors. Their ETPs were equivalent for each tested concentration. This parameter has been shown to predict well the clinical outcome of patients having coagulation disorders and to be useful to monitor the return to an effective haemostasis after BPA treatment [36] [37] [38] .
Conclusion
Characterization of therapeutic proteins during development phases is crucial to understand and predict their safety and efficacy profiles. In this study, we described the characterization of LR769, an unmodified lactorecombinant-activated factor VII intended to treat haemophilia A or B patients with inhibitors. Data show appropriate primary sequence, PTMs and secondary structure as well as similar functionality and product-derived impurities than comparator. The LR769 programme aims at ensuring the availability of a new safe, affordable and effective BPA through the use of rabbits as bioreactors.
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